MedTrace Logo

Olive Oil Supplementation for Heart Failure With Reduced Ejection Fraction

NCT07644806 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-06-12

No results posted yet for this study

Summary

The OLEA-HF study aims to explore whether daily supplementation of extra-virgin olive oil (EVOO) for 12 weeks during participation in a cardiac rehabilitation program (standard of care) is feasible in patients with heart failure with reduced ejection fraction (HFrEF). The investigators will also determine the effects of EVOO on functional capacity and quality of life.

Conditions

  • Heart Failure With Reduced Ejection Fraction (HFrEF)

Interventions

OTHER

Extra-virgin olive oil

At least 4 tablespoons of extra-virgin olive oil per day

Sponsors & Collaborators

  • Old Dominion University

    lead OTHER

Principal Investigators

  • Salvatore Carbone, PhD, RDN · Macon & Joan Brock Virginia Health Sciences at Old Dominion University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2027-12-31
Completion
2028-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07644806 on ClinicalTrials.gov